A DCAF1 Ligand Designed for Targeted Protein Degradation
compound 13
DCAF1 binder preclinical, applied to targeted protein degradation from HTS + optimization ACS Med. Chem. Lett. June 2, 2023 Novartis, Basel, CH
Other molecules you may be interested in
"compound 10"
The Genentech XIAP E3-ligase degrader, compound 10 , has an interesting mechanism of action, triggering the degradation of its target (XIAP) by ubiquitylation of the small molecule. The molecule behaves as a lysine mimetic, accepting ubiquitin from the targeted E3 complex, promoting XIAP’s own degradation. As E3 ligases are often difficult to [...]
CFT1946
CFT1946 from C4 Therapeutics is a potent, selective, and orally bioavailable bifunctional degrader of mutant BRAF in Ph. I/II for the treatment of BRAF-driven solid tumors, alone and in combo with a MEK1/2 inhibitor (trametinib) (NCT05668585). BRAF-V600X is clinically validated with approved drugs (e.g. vemurafenib), but traditional inhibitors face challenges in selectivity over wildtype BRAF and can cause paradoxical RAF activation. [...]
NX-5948
Nurix recently unveiled their second clinical BTK degrader, NX-5948, which is in Ph. Ia/Ib for patients with advanced B-cell malignancies (NCT05131022). A novel CRBN ligand was developed to remove IKZF1/3 degradation activity, distinguishing NX-5948 from their earlier disclosed dual BTK-IKZF1/3 degrader NX-2127, which is currently in Ph. I for relapsed/refractory B-cell malignancies (NCT04830137). The potent BTK degrader NX-5948 has displayed CNS penetration preclinically, allowing for primary CNS lymphoma (PCNSL) participants to be included in the clinical study.
CC-92480
CC-92480 (Celgene/Bristol Myers Squibb (BMS) oral in vivo CRBN-based selective IKZF1/3 degrader)
